Speedel: Dr Alice Huxley, CEO & President

19:00 EST 30 Nov 2006 | PharmaTelevision

Dr Alice Huxley talks to Fintan Walton about setting up Speedel and her motivations for doing so, following the merger of Ciba-Geigy and Sandoz in 1996 to create Novartis. They discuss the company's drug development programmes and how its lead compound is nearing launch. Dr Huxley also reviews the company’s business strategy and the important balance between collaborative R&D and in-house development. Finally, she outlines the reasoning behind the decision to float Speedel on the Swiss stock exchange and discusses what the future might hold for the small biotechnology company.

Original Article: Speedel: Dr Alice Huxley, CEO & President


More From BioPortfolio on "Speedel: Dr Alice Huxley, CEO & President"

Quick Search


Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...